MedTrace Logo

Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome

NCT00705172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 41

Last updated 2023-11-02

No results posted yet for this study

Summary

This study is conducted in Europe. The aim of this observational study is to collect data from children with Prader-Willi Syndrome, who have been treated off-label with Norditropin® for more than 12 months to seek approval for Norditropin® treatment with Prader-Willi Syndrome.

Conditions

Interventions

DRUG

somatropin

Prader-Willi syndrome children treated with at least one dose of Norditropin®

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Denmark
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00705172 on ClinicalTrials.gov